Who are Ivosidenib Oral Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AG-120.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ivosidenib-oral-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ivosidenib Oral Tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivosidenib Oral Tablet (Ivosidenib Oral Tablet) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IDH1 inhibitor. Area: Oncology.

phase 3 IDH1 inhibitor IDH1 (isocitrate dehydrogenase 1, mutant) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ivosidenib Oral Tablet (Ivosidenib Oral Tablet) — Servier Bio-Innovation LLC. Ivosidenib is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that blocks the production of the oncometabolite 2-hydroxyglutarate, thereby promoting differentiation and apoptosis of IDH1-mutant cancer cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ivosidenib Oral Tablet TARGET	Ivosidenib Oral Tablet	Servier Bio-Innovation LLC	phase 3	IDH1 inhibitor	IDH1 (isocitrate dehydrogenase 1, mutant)
AG-120	AG-120	Institut de Recherches Internationales Servier	phase 3	IDH1 inhibitor	IDH1 (isocitrate dehydrogenase 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IDH1 inhibitor class)

Institut de Recherches Internationales Servier · 1 drug in this class
Servier Bio-Innovation LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ivosidenib Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/ivosidenib-oral-tablet. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab